KRAS and neoplasm: The STK11 gene encodes for the serine/threonine kinase 11 which, when inactive, has been shown to limit the density of tumor infiltrating lymphocytes and therefore prevent an effective response to immunotherapy, especially in KRAS‐mutant tumors.36 Although now considered to be a strong and possible causal factor in ICIs' resistance, its role as a contributing factor in HPD is still unknown.